PARP16 and small cell lung carcinoma: Compared to other PARP1 inhibitors, talazoparib displays higher efficacy in reducing proliferation and inducing cell death in small cell lung cancer (SCLC) cell lines thanks to the parallel inhibition of PARP1 and PARP16, suggesting that the latter is an attractive therapeutic target for the treatment of different types of cancers (Fig. 5I) (Palve et al., 2022).